We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel (ALCOOTAX)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01448759
First Posted: October 7, 2011
Last Update Posted: April 24, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Institut Curie
October 6, 2011
October 7, 2011
April 24, 2015
October 2011
February 2012   (Final data collection date for primary outcome measure)
Evaluation of plasma alcohol [ Time Frame: One year ]
Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)
Same as current
Complete list of historical versions of study NCT01448759 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel
Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion
The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.
In this study, there is no experimental treatment, or experimental care.
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Tumors
Other: blood sampling
Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule.
  • Patient with bitherapy are eligible only if the taxane is the first infusion.
  • All type of tumor.
  • Age>18 years old.
  • Signed written informed consent.

Exclusion Criteria:

  • Patient under 18.
  • Patient with bitherapy, if docetaxel or paclitaxel is not administered first.
  • Patient deprived of liberty.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01448759
IC 2011-03
No
Not Provided
Not Provided
Institut Curie
Institut Curie
Not Provided
Principal Investigator: LE TOURNEAU Christophe, MD Institut Curie
Institut Curie
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top